MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-15-2026
Vivos Therapeutics Operating Income 2011-2026 | VVOS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Vivos Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.9 M | -11.2 M | -17.3 M | -25 M | -20.4 M | -12 M | -10.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.6 M | -25 M | -16.6 M |
Quarterly Operating Income Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.73 M | -4.86 M | -3.92 M | - | -2.64 M | -1.94 M | -3.78 M | - | -3.64 M | -4.52 M | -5 M | - | -5.41 M | -6.96 M | -6.82 M | - | -5.5 M | -4.06 M | -3.41 M | - | -1.82 M | -1.42 M | -2.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.42 M | -6.96 M | -4.06 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M |  USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 7.06 | -31.04 % | $ 1.06 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.59 | 4.06 % | $ 134 M |  France |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.22 | 2.55 % | $ 1.35 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 11.51 | 3.69 % | $ 326 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 17.11 | 0.44 % | $ 401 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.57 | -5.8 % | $ 35.5 M | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 65.93 | 14.48 % | $ 3.6 B |  Britain |
 |
Delcath Systems
DCTH
|
660 K | $ 11.3 | -1.99 % | $ 405 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.04 | -0.95 % | $ 17.6 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 26.02 | 0.31 % | $ 220 M | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.85 | -2.23 % | $ 35.6 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 4.58 | -5.08 % | $ 970 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 12.24 | -1.61 % | $ 485 M |  Curacao |
 |
Insulet Corporation
PODD
|
474 M | $ 151.79 | -9.4 % | $ 10.7 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 89.29 | -0.82 % | $ 12.1 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.44 | 1.03 % | $ 6.77 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.97 | 0.9 % | $ 1.15 B | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 46.31 | -4.02 % | $ 1.36 B | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 85.95 | 0.12 % | $ 2.99 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 83.01 | 0.12 % | $ 48.5 B | USA |
 |
Stryker Corporation
SYK
|
4.89 B | $ 291.15 | -1.39 % | $ 111 B | USA |
 |
Tactile Systems Technology
TCMD
|
29.3 M | $ 24.93 | 3.66 % | $ 570 M | USA |
 |
TransMedics Group
TMDX
|
109 M | $ 71.31 | -24.88 % | $ 2.42 B | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 18.04 | -7.11 % | $ 1.23 B | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.37 | -2.1 % | $ 64.2 M | USA |